FULC Quote, Financials, Valuation and Earnings

Axogen has a net margin of 69.26% compared to Fulcrum Therapeutics's net margin of 0.91%. Fulcrum Therapeutics's return on equity of -8.07% beat Axogen's return on equity of -10.21%.

Fulcrum Therapeutics has a consensus price target of $5.67, signalling upside risk potential of 81.62%. On the other hand Axogen has an analysts' consensus of $25.00 which suggests that it could grow by 44.76%. Given that Fulcrum Therapeutics has higher upside potential than Axogen, analysts believe Fulcrum Therapeutics is more attractive than Axogen.

Fulcrum Therapeutics has a beta of 2.198, which suggesting that the stock is 119.83% more volatile than S&P 500. In comparison Axogen has a beta of 1.024, suggesting its more volatile than the S&P 500 by 2.388%.

Fulcrum Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulcrum Therapeutics pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

Fulcrum Therapeutics quarterly revenues are $80M, which are larger than Axogen quarterly revenues of $49.4M. Fulcrum Therapeutics's net income of -$16.6M is lower than Axogen's net income of $450K. Notably, Fulcrum Therapeutics's price-to-earnings ratio is -- while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics is -- versus 4.08x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

Elanco Animal Health has a net margin of 69.26% compared to Fulcrum Therapeutics's net margin of -0.78%. Fulcrum Therapeutics's return on equity of -8.07% beat Elanco Animal Health's return on equity of 5.48%.

Fulcrum Therapeutics has a consensus price target of $5.67, signalling upside risk potential of 81.62%. On the other hand Elanco Animal Health has an analysts' consensus of $15.42 which suggests that it could grow by 47.67%. Given that Fulcrum Therapeutics has higher upside potential than Elanco Animal Health, analysts believe Fulcrum Therapeutics is more attractive than Elanco Animal Health.

Fulcrum Therapeutics has a beta of 2.198, which suggesting that the stock is 119.83% more volatile than S&P 500. In comparison Elanco Animal Health has a beta of 1.439, suggesting its more volatile than the S&P 500 by 43.861%.

Fulcrum Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elanco Animal Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulcrum Therapeutics pays -- of its earnings as a dividend. Elanco Animal Health pays out -- of its earnings as a dividend.

Fulcrum Therapeutics quarterly revenues are $80M, which are smaller than Elanco Animal Health quarterly revenues of $1B. Fulcrum Therapeutics's net income of -$16.6M is lower than Elanco Animal Health's net income of -$8M. Notably, Fulcrum Therapeutics's price-to-earnings ratio is -- while Elanco Animal Health's PE ratio is 15.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics is -- versus 1.17x for Elanco Animal Health. Usually stocks with elevated PS ratios are considered overvalued.

Integra Lifesciences Holdings has a net margin of 69.26% compared to Fulcrum Therapeutics's net margin of 4.39%. Fulcrum Therapeutics's return on equity of -8.07% beat Integra Lifesciences Holdings's return on equity of -0.45%.

Fulcrum Therapeutics has a consensus price target of $5.67, signalling upside risk potential of 81.62%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $26.25 which suggests that it could grow by 17.45%. Given that Fulcrum Therapeutics has higher upside potential than Integra Lifesciences Holdings, analysts believe Fulcrum Therapeutics is more attractive than Integra Lifesciences Holdings.

Fulcrum Therapeutics has a beta of 2.198, which suggesting that the stock is 119.83% more volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.861%.

Fulcrum Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulcrum Therapeutics pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Fulcrum Therapeutics quarterly revenues are $80M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $442.6M. Fulcrum Therapeutics's net income of -$16.6M is lower than Integra Lifesciences Holdings's net income of $19.4M. Notably, Fulcrum Therapeutics's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics is -- versus 1.07x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Orthofix Medical has a net margin of 69.26% compared to Fulcrum Therapeutics's net margin of -13.52%. Fulcrum Therapeutics's return on equity of -8.07% beat Orthofix Medical's return on equity of -22.96%.

Fulcrum Therapeutics has a consensus price target of $5.67, signalling upside risk potential of 81.62%. On the other hand Orthofix Medical has an analysts' consensus of $24.30 which suggests that it could grow by 47.01%. Given that Fulcrum Therapeutics has higher upside potential than Orthofix Medical, analysts believe Fulcrum Therapeutics is more attractive than Orthofix Medical.

Fulcrum Therapeutics has a beta of 2.198, which suggesting that the stock is 119.83% more volatile than S&P 500. In comparison Orthofix Medical has a beta of 1.058, suggesting its more volatile than the S&P 500 by 5.812%.

Fulcrum Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulcrum Therapeutics pays -- of its earnings as a dividend. Orthofix Medical pays out -- of its earnings as a dividend.

Fulcrum Therapeutics quarterly revenues are $80M, which are smaller than Orthofix Medical quarterly revenues of $215.7M. Fulcrum Therapeutics's net income of -$16.6M is higher than Orthofix Medical's net income of -$29.1M. Notably, Fulcrum Therapeutics's price-to-earnings ratio is -- while Orthofix Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulcrum Therapeutics is -- versus 0.79x for Orthofix Medical. Usually stocks with elevated PS ratios are considered overvalued.